Compare NIO Inc. (NIO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs Pfizer Inc — how do they compare? NIO Inc. trades at $3.45 (market cap $8.67B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 18.4× NIO Inc.'s market cap, and Pfizer Inc pays a 6.14% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and Pfizer Inc for 158 Days on average.
| NIO | PFE | |
|---|---|---|
Market Cap | $8.67B | $159.59B |
Volume | 25,622,800 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $29.02 |
52-Week Low | $3.37 | $23.67 |
Typical Hold Time | 81 Days | 158 Days |
Enterprise Value | $6.57B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.54, down 55% from its 52-week high, with a bearish technical signal despite recent earnings beats. The company shows improving revenue growth (2025: $87.5B) and narrowing losses (net margin: -17.8% in 2025 vs -34.5% in 2024), supported by a strategic battery-swap partnership with Geely. However, negative cash flow (-$10.9B in 2024) and high debt ($20.6B total debt) remain concerns.
The stock offers speculative upside to the $6.23 analyst target (76% potential) but faces significant execution risks in China's competitive EV market. Investors must weigh improving fundamentals against persistent profitability challenges and macroeconomic headwinds.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
